# Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT02627443** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Fallopian Tube Carcinoma
- Metastatic Ovarian Carcinoma
- Metastatic Primary Peritoneal Carcinoma
- Ovarian Endometrioid Tumor
- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7

## Interventions

- **DRUG:** Berzosertib
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02627443
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-16
- **Primary completion:** 2024-10-04
- **Final completion:** 2026-06-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627443, "Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02627443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*